GANX
NASDAQGain Therapeutics Inc.
Website
News25/Ratings4
News · 26 weeks25-100%
2025-10-262026-04-19
Mix1190d
- SEC Filings4(36%)
- Other4(36%)
- Insider2(18%)
- Earnings1(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Mack Gene4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Fuggetta Gianluca4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- SECSEC Form 10-K filed by Gain Therapeutics Inc.10-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateBETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. "We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without a GBA1 mutation. The promising impact GT-02287 has on the cau
- PRGain Therapeutics to Present at the 38th Annual ROTH ConferenceBETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference, being held March 22-24, 2026, in Dana Point, CA. Fireside Chat Details Date: Monday, March 23, 2026 Time: 11:30 a.m. PT Access a live webcast or a replay of the fireside chat here or visit the "Investors & Media/News & Events" section of the Company's website at https://gaintherapeutics.com
- SECGain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF glucosylsphingosine Additional MDS-UPDRS data demonstrate continued durability at day 150 of GT-02287 administration Novel chemical series, headlined by advanced lead GT-04686, is ready for IND-enabling studies for the treatment of Parkinson's disease and other neurological disorders BETHESDA, Md., March 18, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and developm
- PRGain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory UpdateInterim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial of GT-02287 in 3Q26 after submitting additional preclinical data requested by FDA in support of an IND BETHESDA, Md., March 12, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations at the AD/PD ™ 2026 International Conference on Alzheimer's and Parkinson's Disease and Related Neurological D
- PRGain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th. Fireside Chat Details Date: Wednesday, February 25, 2026 Time: 1:20 p.m. ET To access a replay of the fireside chat visit here or the "Investors & Media/News & Events" section of the Company'
- SECGain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference WeekBETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference ("JPM week") including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event. Information on all events is below. The 9th Annual Sachs Neuroscience Innovation ForumDate: January 11, 2026Format: Presentation and one-on-one meetings with managemen
- PRGain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson's disease (PD) with or without a GBA1 mutation that further supports the disease-modifying potential of GT-02287. In participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) at baseline, GluSph decreased by an average of 81% after 90 days of treatment with GT-02287. Elev
- PRGain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's DiseaseBETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it will host a virtual key opinion leader (KOL) event, "Understanding GCase Substrates in Parkinson's Disease: Perspectives on Biomarkers and Disease Modification, Contextualizing emerging biomarker data from the Phase 1b clinical study of GT-02287". Featured Key Opinion Leaders (KOLs) will be Roy Alcalay, M.D., M.Sc., Chief of Movement Disorders Division, Tel Aviv Sourasky Medical Center, Professor of Neurology, Tel A
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's DiseaseResults showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson's disease (PD) KOL event planned for early January to discuss the results; registration information herein BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next ge
- SECSEC Form S-8 filed by Gain Therapeutics Inc.S-8 - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECSEC Form 424B5 filed by Gain Therapeutics Inc.424B5 - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model GT-02287 improves mitochondrial function by facilitating GCase trafficking to the mitochondria in patient-derived fibroblasts harboring GBA1 mutation BETHESDA, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation was made at the Society
- SECSEC Form 10-Q filed by Gain Therapeutics Inc.10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate UpdatePresented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson's Disease with or without GBA1 mutations during 3Q 2025 Received approval from the Australian health authorities to extend the duration of the Phase 1b study, allowing participants to continue treatment with GT-02287 for a total of 12 months; with a majority of subjects electing to participate in the study extension Analysis of functional changes and biomarker activity at 90 days expected to be available during 4Q
- SECAmendment: SEC Form S-3/A filed by Gain Therapeutics Inc.S-3/A - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics to Present at Neuroscience 2025BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the Society for Neuroscience annual meeting, Neuroscience 2025, being held November 15th–19th in San Diego, CA. Details are as follows: Session Type: PosterSession Number: PSTR438Session Title: Developing Parkinson's Disease Therapeutic Strategies Using Cellular Models Poster Title: "GT-02287, a small molecule allosteric modulator of lysosomal enzyme glucocerebrosidase (GCase), acts at both lysos